TRT side effects: separating real risks from gym-bro myths

What did @kmartfit actually say?

The core argument here is that TRT's bad reputation is borrowed from bodybuilding, not earned on its own. The claim is simple: TRT doses (around 150 mg/week) are so far below bodybuilding doses (600-1200 mg/week) that comparing their side effect profiles is like comparing one cup of coffee to twenty. "The purpose of TRT is only to bring low testosterone men back to normal," so the side effects largely disappear when you're in that replacement range.

The coffee analogy is doing a lot of rhetorical work here. It's memorable, it's intuitive, and it's mostly in the right direction. But analogies aren't evidence, and the claim that men on TRT "really only see benefits and not too many side effects at all" is a significant overstatement that deserves scrutiny.

Does the science back this up?

Partially, yes. The dose-dependency of testosterone's adverse effects is well-documented, and the cardiovascular panic around TRT has genuinely been overblown in popular media. But "not too many side effects at all" glosses over real risks that persist even at replacement doses.

The 2018 TRAVERSE trial precursor data and the landmark 2016 Testosterone Trials (Snyder et al., NEJM) showed modest cardiovascular signal increases in coronary artery plaque even at therapeutic doses. Erythrocytosis, the elevation of red blood cell mass, is one of the most consistent side effects at standard TRT doses and is not trivial. A 2023 review by Bhasin et al. in the New England Journal of Medicine confirmed that hematocrit elevation occurs in roughly 18-21% of men on injectable testosterone at therapeutic doses. Infertility risk via suppression of the hypothalamic-pituitary-gonadal axis is another real consideration that the video skips entirely. These aren't bodybuilding complications. They happen at 150 mg/week.

What did they get wrong (or right)?

Credit where it's due: the dose comparison is legitimate and the stigma point is fair. The literature does support that supraphysiologic testosterone use, not replacement therapy, is responsible for most of the dramatic cardiovascular and psychiatric adverse events associated with anabolic steroid use. Hickson et al. and decades of sports medicine research back that up.

Where the video goes wrong is the implication that TRT is essentially side-effect-free. That's not accurate. The specific claims about heart attack and stroke being uniquely a bodybuilding problem deserve nuance. The 2010 Basaria et al. trial published in NEJM was actually halted early due to increased cardiovascular events in older men on TRT. That trial had methodological limitations, but it exists. The TRAVERSE trial (Lincoff et al., NEJM, 2023) ultimately showed TRT was non-inferior to placebo for major cardiovascular events in men with hypogonadism and elevated cardiovascular risk, which is genuinely reassuring, but that's a specific population with monitoring. Saying cardiovascular risk is purely a bodybuilding problem is an oversimplification that could give men a false sense of security.

What should you actually know?

Dose matters enormously, and that point is correct. But TRT is still a medical intervention with real side effects that require monitoring, not a consequence-free correction of a deficiency. The actual list of side effects that occur even at therapeutic doses includes erythrocytosis, testicular atrophy, reduced sperm production, acne, sleep apnea worsening, and mood changes in some individuals.

The cardiovascular picture is more complicated than either "TRT causes heart attacks" or "TRT is totally safe." The TRAVERSE data is reassuring for non-fatal cardiovascular events, but the same trial found a statistically significant increase in pulmonary embolism and atrial fibrillation in the TRT group. Those are not bodybuilding-dose complications. Anyone considering TRT should be monitored by a licensed provider with baseline labs, hematocrit checks, and regular follow-up. That context is what's missing from a 60-second TikTok, and it's the context that matters.